Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Feb 8:13:50.
doi: 10.1186/1471-244X-13-50.

The nature of relapse in schizophrenia

Affiliations
Review

The nature of relapse in schizophrenia

Robin Emsley et al. BMC Psychiatry. .

Abstract

Background: Multiple relapses characterise the course of illness in most patients with schizophrenia, yet the nature of these episodes has not been extensively researched and clinicians may not always be aware of important implications.

Methods: We critically review selected literature regarding the nature and underlying neurobiology of relapse.

Results: Relapse rates are very high when treatment is discontinued, even after a single psychotic episode; a longer treatment period prior to discontinuation does not reduce the risk of relapse; many patients relapse soon after treatment reduction and discontinuation; transition from remission to relapse may be abrupt and with few or no early warning signs; once illness recurrence occurs symptoms rapidly return to levels similar to the initial psychotic episode; while most patients respond promptly to re-introduction of antipsychotic treatment after relapse, the response time is variable and notably, treatment failure appears to emerge in about 1 in 6 patients. These observations are consistent with contemporary thinking on the dopamine hypothesis, including the aberrant salience hypothesis.

Conclusions: Given the difficulties in identifying those at risk of relapse, the ineffectiveness of rescue medications in preventing full-blown psychotic recurrence and the potentially serious consequences, adherence and other factors predisposing to relapse should be a major focus of attention in managing schizophrenia. The place of antipsychotic treatment discontinuation in clinical practice and in placebo-controlled clinical trials needs to be carefully reconsidered.

PubMed Disclaimer

References

    1. Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S. et al.Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch Gen Psychiatry. 1999;56:241–247. doi: 10.1001/archpsyc.56.3.241. - DOI - PubMed
    1. Kane JM. Treatment strategies to prevent relapse and encourage remission. J Clin Psychiatry. 2007;68(Suppl 14):27–30. - PubMed
    1. Wyatt RJ. Research in schizophrenia and the discontinuation of antipsychotic medications. Schizophr Bull. 1997;23:3–9. doi: 10.1093/schbul/23.1.3. - DOI - PubMed
    1. Lieberman JA, Alvir JM, Koreen A, Geisler S, Chakos M, Sheitman B. et al.Psychobiologic correlates of treatment response in schizophrenia. Neuropsychopharmacology. 1996;14:13S–21S. doi: 10.1016/0893-133X(95)00200-W. - DOI - PubMed
    1. Alvarez-Jimenez M, Priede A, Hetrick SE, Bendall S, Killackey E, Parker AG. et al.Risk factors for relapse following treatment for first episode psychosis: a systematic review and meta-analysis of longitudinal studies. Schizophr Res. 2012;139:116–128. doi: 10.1016/j.schres.2012.05.007. - DOI - PubMed

Publication types